Procalcitonin as Biomarker of Antibiotic Effectivity in Community-Acquired Pneumonia  

Oleh:

Faizah, Ana Khusnul ; Winariani ; Yulistiani ; Samirah

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Folia Medica Indonesiana vol. 51 no. 2 (2015), page 96-100.
Topik: procalcitonin; community-acquired pneumonia; antibiotic therapy; biomarker
Fulltext: download-fullpapers-fmi53d72096fdfull.pdf (80.62KB)

Isi artikel

Major therapy for community-acquired pneumonia (CAP) is antibiotics. Procalcitonin used as the measure of antibiotics effectiveness. Procalcitonin is specific biomarker that elevates in acute bacterial infection. This study aimed to analyze procalcitonin as effective antibiotics biomarker in CAP patients hospitalized at Pulmonology Department Dr. Soetomo Teaching Hospital. This study was performed by cohort prospective data and analyzed by descriptively. Data were assessed at before antibiotics, day 3 and day 5 after antibiotics therapy. Nineteen community-acquired pneumonia were enrolled. Serum procalcitonin before antibiotic therapy , day 3 and day 5 antibiotics therapy in CAP are 0.51+ 0.19 (0.28-0.89) ng/ml, 0.53+ 0.24 (0.08-0.93) ng/ml and 0.43+ 0.24 (0.00-0.83) ng/ml. Serum procalcitonin in CAP with sepsis patients are 0.51+ 0.19 (0.28-0.89) ng/ml (before antibiotic therapy), 0.40 + 0.26 (0.08-0.74) ng/ml (day 3) and 0.22 + 0.13 (0.00-0.32) ng/ml (day 5). Serum Procalcitonin in CAP with pulmonary TB are 0.52 + 0.18 (0.38-0.83) ng/ml, 0.55 + 0.25 (0.23-0.89) ng/ml dan 0.57 + 0.16 (0.41-0.82) ng/ml. Serum procalcitonin in CAP with sepsis and pulmonary TB are 0.55 + 0.12 (0.38-0.70) ng/ml, 0.56 + 0.15 (0.42-0.73) ng/ml dan 0.47 + 0.15 (0.33-0.64) ng/ml. Procalcitonin of 60% CAP with sepsis patients, 20% CAP with pleural effusion patients and no patients of CAP with pulmonary TB reach <0.26 ng/ml. In conclusion, procalcitonin is not useful biomarker in CAP. (FMI 2015;51:96-100)

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali